Evidence map›Paper›PMID 40388621›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Click-constructed modular signal aptamer chimeras enable receptor-independent degradation of membrane proteins.

Wanlin Xie, Weidi Sun, Qin Li, Yang Dang, Lele Ma, Yuan Liu, Hui Zhang, Fengli Qu, Weihong Tan

Erratum issuedAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Wanlin XieSchool of Materials Science and Engineering, Tianjin University, Tianjin 300350, China.
Weidi SunZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China.
Qin LiZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China.
Yang DangSchool of Materials Science and Engineering, Tianjin University, Tianjin 300350, China.
Lele MaZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China.ORCID 0009-0006-5210-169X
Yuan LiuZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China.
Hui ZhangZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China.
Fengli QuZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China.ORCID 0009-0003-2248-8609
Weihong TanZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China.

Funding

foundation of Hangzhou Institute of Medicine, Chinese Academy of Sciences 2024ZZBS08MOST | National Key Research and Development Program of China (NKPs) 2021YFA0910100National Natural Science Foundation of China 22107093National Nature Science Foundation of China 22274141Natural Science Foundation of Shandong Province ZR2022ZD28Pioneer R&D Program of Zhejiang 2022C03031 2023SDYXS0002Research Funds of Hangzhou Institute for Advanced Study, UCAS 2024HIAS-V008 2024HIAS-Y012Zhejiang Provincial Health Commission Research Foundation WKJ-ZJ-242Zhejiang Provincial Natural Science Foundation of China ZCLMS25C0501
6 · The paper itself

Abstract

Cell-membrane proteins are critical mediators of signal transduction, playing essential roles in disease occurrence and progression. The emerging LYTACs (Lysosome-targeting chimeras) technology combines drug-targeting strategies with lysosomal degradation, providing a novel approach to drug development and offering new possibilities for disease therapy. However, the clinical applicability of current LYTAC degraders is limited by the variable expression of lysosome-targeting receptors (LTRs) in tissues. To overcome this limitation, we herein hijacked a YXXØ sorting signal that derived from lysosome-associated membrane protein 2a (LAMP-2a) to develop a signal aptamer platform (SApt), which exhibits high specificity for targeting membrane proteins and inducing efficient lysosomal degradation. SApts were synthesized by conjugating the YXXØ signal peptide to the aptamer's terminus through a click reaction. Our study demonstrated that SApts efficiently degrade disease-associated membrane proteins, such as PTK7, Met, and NCL, based on the inherent signals rather than specific LTR. The potent antitumor efficacy of SApts was further confirmed in a xenograft tumor model, where in vivo degradation of PTK7 was observed. Collectively, our work provides insights into the development of a simple and universal lysosomal degradation platform with potential translational value in clinical treatment.

Indexed as

Aptamers, NucleotideMembrane ProteinsProtein Sorting SignalsAnimalsCell Adhesion MoleculesCell Line, TumorClick ChemistryHumansLysosomal-Associated Membrane Protein 2LysosomesMicePlatelet Membrane GlycoproteinsProteolysisReceptor Protein-Tyrosine KinasesSignal TransductionXenograft Model Antitumor AssaysAptamers, NucleotideCell Adhesion MoleculesLysosomal-Associated Membrane Protein 2Membrane ProteinsPlatelet Membrane GlycoproteinsProtein Sorting SignalsPTK7 protein, humanReceptor Protein-Tyrosine Kinasesaptamerslysosome-targeting receptorsmembrane proteinssorting signal

Identifiers

PMID40388621
PMCPMC12130886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.